Test Demodex Blepharitis: A Prevalent But Commonly Missed Lid Margin Disease That Impacts Millions

Article

Advertorial: Demodex Blepharitis: A Prevalent But Commonly Missed Lid Margin Disease That Impacts Millions


Demodex blepharitis is a common eyelid margin disease affecting approximately 25 million eye care patients in the U.S.1-2 Untreated, Demodex blepharitis can lead to symptoms such as ocular surface inflammation and may impact daily activities. Despite its high prevalence, awareness and knowledge of Demodex blepharitis remains low. Fortunately, optometrists already have the tools necessary to diagnose it if they know what to look for.


Click the link above to download the full article.


References:

1. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes, a pathognomonic sign. Clin Ophthalmol. 2022;16:1153–64.

2. Saydah SH, Gerzoff RB, Saaddine JB, Zhang X, Cotch MF. Eye care among US adults at high risk for vision loss in the United States in 2002 and 2017. JAMA Ophthalmol. 2020;138(5):479-489.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.